The relationship between Helicobacter pylori seropositivity and COPD

Thorax. 2015 Oct;70(10):923-9. doi: 10.1136/thoraxjnl-2015-207059. Epub 2015 May 29.

Abstract

Rationale: Chronic systemic infections such as those with Helicobacter pylori (H. pylori) may contribute to the evolution and progression of chronic obstructive pulmonary disease (COPD). Using data from the Lung Health Study (LHS), we determined the relationship of H. pylori infection with the severity and progression of COPD.

Methods: Using an immunoassay, we measured H. pylori immunoglobulin G (IgG) antibody titres in serum samples of 4765 patients with mild-to-moderate COPD. We then determined their relationship with the individual's FEV1 and the rate of decline in FEV1 and mortality over 11 years using multiple regression analysis.

Results: Approximately 18% of the patients were seropositive to H. pylori and these individuals demonstrated lower FEV1 (L) values at every study visit compared with individuals who were seronegative for H. pylori (p value=0.00012). However, patients with seropositivity to H. pylori were on average 0.012 m shorter than those with seronegativity (p value=0.0015). The significant relationship between FEV1 and H. pylori seropositivity disappeared when FEV1 per cent predicted (FEV1pp) was used (p value=0.45). H. pylori seropositive individuals had greater circulating C reactive protein (CRP) levels compared with H. pylori seronegative individuals (p value=0.012), and had increased risk of cardiovascular mortality (relative risk 1.61, p=0.05).

Conclusions: H. pylori infection was associated with reduced lung function that is most likely due to the effect of the bacterium on lung growth earlier in life. It is also associated with systemic inflammation and increased risk of cardiovascular mortality in patients with COPD.

Trial registration numbers: NCT00000568 and NCT00000569.

Keywords: COPD epidemiology; Respiratory Infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Bacterial / blood*
  • Cohort Studies
  • Female
  • Forced Expiratory Volume / physiology
  • Helicobacter Infections / complications*
  • Helicobacter Infections / mortality
  • Helicobacter Infections / physiopathology
  • Helicobacter pylori / immunology*
  • Humans
  • Immunoglobulin G / blood
  • Male
  • Middle Aged
  • Pulmonary Disease, Chronic Obstructive / microbiology*
  • Pulmonary Disease, Chronic Obstructive / mortality
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Regression Analysis
  • Risk Factors

Substances

  • Antibodies, Bacterial
  • Immunoglobulin G

Associated data

  • ClinicalTrials.gov/NCT00000568
  • ClinicalTrials.gov/NCT00000569